Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript

Nobuko Kato
Chief Communications & Investor Relations Officer

Thank you for taking time out of your busy schedules to join us today for Astellas R&D Day. I am Kato, Chief Communications and IR Officer, and I’ll be serving as a moderator today. It is a pleasure to have you here.

Following our presentation, we will move on to the Q&A session. The presentation will be based on the presentation materials available on our website. Simultaneous interpretation in Japanese and English will be provided throughout the event, including the Q&A session. Please note that we cannot guarantee the accuracy of the simultaneous interpretation. [Operator Instructions]

Please note the following. This material or presentation and answers and statement for the company in the Q&A session by representatives includes forward-looking statements based on assumptions and beliefs in light of the information currently available and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors. They contain information on pharmaceuticals, including the product under development, but it is not intended to make any representations or advertisement of these preparations. The data we are going to introduce today is based upon the contents presented at the conference meeting.